ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    odonate
Previous Study | Return to List | Next Study

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, MBC (CONTESSA) (CONTESSA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03326674
Recruitment Status : Recruiting
First Posted : October 31, 2017
Last Update Posted : December 7, 2018
Sponsor:
Information provided by (Responsible Party):
Odonate Therapeutics, LLC

October 13, 2017
October 31, 2017
December 7, 2018
December 21, 2017
September 2020   (Final data collection date for primary outcome measure)
PFS [ Time Frame: Approximately 2.5 - 3 years ]
Progression Free Survival
Same as current
Complete list of historical versions of study NCT03326674 on ClinicalTrials.gov Archive Site
  • OS [ Time Frame: Approximately 5 - 5.5 years ]
    Overall Survival
  • ORR [ Time Frame: Approximately 2.5 - 3 years ]
    Objective Response Rate
  • DCR [ Time Frame: Approximately 2.5 - 3 years ]
    Disease Control Rate
  • CNS ORR in patients with CNS metastases at Baseline [ Time Frame: Approximately 2.5 -3 years ]
    CNS Objective Response Rate as assessed by the CNS Independent Review Committee (IRC)
  • CNS PFS in patients with CNS metastases at Baseline or a history of CNS metastases in the intent-to-treat (ITT) population [ Time Frame: Approximately 2.5 -3 years ]
    CNS Progression Free Survival as assessed by the CNS IRC
  • CNS OS in patients with CNS metastases at Baseline or a history of CNS metastases [ Time Frame: Approximately 2.5 -3 years ]
    CNS Overall Survival as assessed by the CNS IRC
  • OS [ Time Frame: Approximately 5 - 5.5 years ]
    Overall Survival
  • ORR [ Time Frame: Approximately 2.5 - 3 years ]
    Objective Response Rate
  • DCR [ Time Frame: Approximately 2.5 - 3 years ]
    Disease Control Rate
  • PRO [ Time Frame: Approximately 2.5 - 3 years ]
    Patient Reported Outcomes - EORTC QLQ-C30 Global Health Status
  • Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0 [ Time Frame: Approximately 5 - 5.5 years ]
    Adverse Events will be collected at each visit and at unscheduled visits, as clinically indicated
  • Incidence of clinical laboratory abnormalities as assessed by CBC, serum chemistry and coagulation testing [ Time Frame: Approximately 5 - 5.5 years ]
    Laboratory data will be collected at each visit, and unscheduled visits as appropriate
  • Peak plasma concentration (Cmax) of tesetaxel [ Time Frame: [Approximately 2.5-3.0 years] Pre-dose and 0.5 hour post-dose on Day 1 of Cycle 1, 2 and 3 and anytime on Day 15 +/- 2 days of Cycle 1 and 2 (cycles are 21 days) ]
    Maximum plasma concentration (Cmax) of tesetaxel
  • Area under the plasma concentration versus time curve (AUC) of tesetaxel [ Time Frame: [Approximately 2.5-3.0 years] Pre-dose and 0.5 hour post-dose on Day 1 of Cycle 1, 2 and 3 and anytime on Day 15 +/- 2 days of Cycle 1 and 2 (cycles are 21 days) ]
    Area under the curve (AUC) of tesetaxel
  • PRO [ Time Frame: Approximately 2.5 - 3 years ]
    Patient Reported Outcomes - EORTC QLQ-C30 Global Health Status
  • Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 [ Time Frame: Approximately 5 - 5.5 years ]
    Adverse Events will be collected at each visit and at unscheduled visits, as clinically indicated
  • Incidence of clinical laboratory abnormalities as assessed by CBC, serum chemistry and coagulation testing [ Time Frame: Approximately 5 - 5.5 years ]
    Laboratory data will be collected at each visit, and unscheduled visits as appropriate
  • Peak plasma concentration (Cmax) of tesetaxel [ Time Frame: Up to 30 minutes pre-dose on Day 1 of Cycles 1, 2, 3 and 4 (cycles are 21 days), 0.5, 1, 2, 3, 4, 5 and 6 hours post dose on Day 1 of Cycles 1, 2, 3 and 4 (cycles are 21 days) and on Day 8 and 15 of Cycles 1 and 3 (cycles are 21 days). ]
    Maximum plasma concentration (Cmax) of tesetaxel
  • Area under the plasma concentration versus time curve (AUC) of tesetaxel [ Time Frame: Up to 30 minutes pre-dose on Day 1 of Cycles 1, 2, 3 and 4 (cycles are 21 days), 0.5, 1, 2, 3, 4, 5 and 6 hours post dose on Day 1 of Cycles 1, 2, 3 and 4 (cycles are 21 days) and on Day 8 and 15 of Cycles 1 and 3 (cycles are 21 days). ]
    Area under the curve (AUC) of tesetaxel
 
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, MBC (CONTESSA)
Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

The primary objective is to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone in patients with HER2 negative, HR positive LA/MBC previously treated with a taxane in the neoadjuvant or adjuvant setting.

Approximately 600 eligible patients will be randomly assigned in a 1:1 ratio to either Arm A (tesetaxel plus a reduced dose of capecitabine) or Arm B (approved dose of capecitabine alone).

This is a multinational, multicenter, randomized, open-label, parallel group Phase 3 study. The primary objective is to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone based on PFS, as assessed by an Independent Radiologic Review Committee (IRC), in patients with HER2 negative, HR positive, LA/MBC previously treated with a taxane in the neoadjuvant or adjuvant setting.

Patients randomly assigned to Arm A (tesetaxel plus a reduced dose of capecitabine) will be administered:

  • Tesetaxel (27 mg/m2) orally once every 21 days on Day 1 of each 21-day cycle; and
  • Capecitabine (825 mg/m2) orally twice daily (in the morning and evening after a meal, for a total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle

Patients randomly assigned to Arm B (approved dose of capecitabine alone) will be administered:

• Capecitabine (1,250 mg/m2) orally twice daily (in the morning and evening after a meal, for a total daily dose of 2,500 mg/m2), beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle Dose modifications for tesetaxel and/or capecitabine are described in the Study protocol.

Patients will be treated until documentation of progressive disease (PD), evidence of unacceptable toxicity, or other decision to discontinue treatment.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Breast Cancer
  • Drug: Tesetaxel and Capecitabine
    Tesetaxel plus reduced dose of Capecitabine vs. approved dose of Capecitabine
  • Drug: Capecitabine
    Capecitabine alone at approved dose
  • Experimental: Arm A: Tesetaxel and Capecitabine
    Tesetaxel (27 mg/m2) orally once every 21 days on Day 1 of each 21-day cycle; and Capecitabine (825 mg/m2) orally twice daily (in the morning and evening after a meal, for a total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
    Intervention: Drug: Tesetaxel and Capecitabine
  • Active Comparator: Arm B: Capecitabine
    Capecitabine (1,250 mg/m2) orally twice daily (in the morning and evening after a meal, for a total daily dose of 2,500 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
    Intervention: Drug: Capecitabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
600
Same as current
March 2023
September 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Female or male patients at least 18 years of age
  2. Histologically or cytologically confirmed breast cancer
  3. HER2 negative disease based on local testing: American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines should be utilized for assessing HER2 status.
  4. HR (ER and/or PgR) positive disease based on local testing: ASCO/CAP guidelines should be utilized for assessing HR status.
  5. Measurable disease per RECIST 1.1 or bone-only disease with lytic component.

    • Patients with bone-only metastatic cancer must have a lytic or mixed lytic-blastic lesion that can be accurately assessed by computerized tomography (CT) or magnetic resonance imaging (MRI). Patients with bone-only disease without a lytic component (ie, blastic-only metastasis) are not eligible.
    • Known metastases to the central nervous system (CNS) are permitted but not required. The following criteria apply:

      • Patients must be neurologically stable and either off corticosteroids or currently treated with a maximum daily dose of 4 mg of dexamethasone (or equivalent), with no increase in corticosteroid dose within 7 days prior to Randomization
      • Patients with a history of CNS metastases but with no current evidence of CNS lesions following local therapy are eligible
      • Patients may have CNS metastases that are stable or progressing radiologically
      • Patients with current evidence of leptomeningeal disease are not eligible
      • Patients may have untreated brain metastases or previously treated brain metastases, as long as no immediate local CNS-directed therapy is indicated
      • Any prior whole brain radiation therapy must have been completed > 14 days prior to the date of Randomization
      • Prior stereotactic brain radiosurgery is permitted
      • CNS surgical resection must have been completed > 28 days prior to the date of Randomization; patient must have complete recovery from surgery
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
  7. Prior therapy (at least one completed dose) with a taxane-containing regimen in the neoadjuvant or adjuvant setting
  8. Prior therapy with an anthracycline-containing regimen in the neoadjuvant, adjuvant, or metastatic setting, where indicated by local regulation or Investigator judgment.
  9. Prior endocrine therapy with or without a CDK 4/6 inhibitor unless endocrine therapy is not indicated (ie, short relapse-free interval while on adjuvant endocrine therapy [endocrine resistance]; rapidly progressing disease/visceral crisis; or endocrine intolerance). Any targeted therapies approved for HER2 negative, HR positive LA/MBC, including everolimus, are permitted as prior therapy. There is no limit to the number of prior endocrine therapies.
  10. Documented disease recurrence or disease progression of: (a) locally advanced disease that is not considered curable by surgery and/or radiation; or (b) metastatic disease.
  11. Adequate hematologic, hepatic, and renal function, as evidenced by:

    • Absolute neutrophil count (ANC) ≥ 1,500/μL without colony-stimulating factor support
    • Platelet count ≥ 100,000/μL
    • Hemoglobin ≥ 10 g/dL without need for hematopoietic growth factor or transfusion support
    • Total bilirubin < 1.5 × upper limit of normal (ULN); does not apply to patients with Gilbert's syndrome
    • Alanine aminotransferase (ALT) < 3 × ULN unless hepatic metastases are present, then < 5 × ULN
    • Aspartate aminotransferase (AST) < 3 × ULN unless hepatic metastases are present, then < 5 × ULN
    • Alkaline phosphatase < 2.5 × ULN unless hepatic metastases are present, then < 5 × ULN
    • Calculated creatinine clearance ≥ 50 mL/min
    • Serum albumin ≥ 3.0 g/dL
    • Prothrombin time (PT) < 1.5 × ULN or international normalized ratio (INR) < 1.3 and partial thromboplastin time (PTT) < 1.5 × ULN; unless the patient is on a therapeutic anticoagulant
  12. Complete recovery to baseline or Grade 1 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 from adverse effects of prior surgery, radiotherapy, endocrine therapy, and other therapy, as applicable, with the exception of Grade 2 alopecia from prior chemotherapy
  13. Ability to swallow an oral solid-dosage form of medication
  14. A negative serum pregnancy test within 7 days prior to the first dose of Study treatment in women of childbearing potential (ie, all women except those who are post menopause for ≥ 1 year or who have a history of hysterectomy or surgical sterilization)
  15. Women of childbearing potential must use an effective, non-hormonal form of contraception from Screening throughout the Treatment Phase and until 70 days after the last dose of Study treatment

    • Acceptable methods include: copper intrauterine device or double barrier methods, including male/female condoms with spermicide and use of contraceptive sponge, cervical cap, or diaphragm

  16. Male patients must use an effective, non-hormonal form of contraception from Screening throughout the Treatment Phase and until 130 days after last dose of Study treatment

    • Acceptable methods include male/female condoms with spermicide, or vasectomy with medical confirmation of surgical success.

  17. Written informed consent and authorization to use and disclose health information
  18. Ability to comprehend and comply with the requirements of the Study

Exclusion Criteria:

  1. Two or more prior chemotherapy regimens for advanced disease
  2. Prior treatment with a taxane in the metastatic setting
  3. Prior treatment with capecitabine at any dose
  4. Current evidence of leptomeningeal disease
  5. Other cancer that required therapy within the preceding 5 years other than adequately treated: (a) non-melanoma skin cancer or in situ cancer; or (b) following approval by the Medical Monitor, other cancer that has a very low risk of interfering with the safety or efficacy endpoints of the Study
  6. Known human immunodeficiency virus infection, unless well controlled. Patients who are on an adequate antiviral regimen with no evidence of active infection are considered well controlled.
  7. Active hepatitis B or active hepatitis C infection
  8. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with Study participation or investigational product administration or may interfere with the interpretation of Study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this Study.
  9. Presence of neuropathy > Grade 1 per NCI CTCAE version 5.0
  10. History of hypersensitivity to taxanes; hypersensitivity to the solvent does not preclude patient participation in this Study
  11. Anticancer treatment, including endocrine therapy, radiotherapy (except stereotactic brain surgery), chemotherapy, biologic therapy, or therapy in an investigational clinical study, ≤ 14 days prior to the date of Randomization
  12. Major surgery ≤ 28 days prior to the date of Randomization; patient must have complete recovery from surgery
  13. Less than 2 weeks or 5 plasma half-lives (whichever is greater) since last use of a medication or ingestion of an agent, beverage, or food that is a known clinically relevant strong inhibitor or known clinically relevant inducer of the cytochrome P450 (CYP) 3A pathway (patients should discontinue taking any regularly taken medication that is a strong inhibitor or inducer of the CYP3A pathway)
  14. History of hypersensitivity or unexpected reactions to capecitabine, other fluoropyrimidine agents, or any of their ingredients
  15. Known dihydropyrimidine dehydrogenase (DPD) deficiency. Testing for DPD deficiency must be performed where required by local regulations, using a validated method that is approved by local health authorities.
  16. Pregnant or breastfeeding
  17. If, in the opinion of the Investigator, the patient is deemed unwilling or unable to comply with the requirements of the Study
  18. Treatment with brivudine, sorivudine, or its chemically-related analogs ≤ 28 days prior to the date of Randomization
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact: Stew Kroll 650-576-9679 skroll@odonate.com
Contact: Jill Krause 810-208-7254 jkrause@odonate.com
Australia,   Austria,   Belgium,   Canada,   Czechia,   France,   Germany,   Hungary,   Italy,   Korea, Republic of,   Poland,   Singapore,   Spain,   Taiwan,   Thailand,   Ukraine,   United Kingdom,   United States
 
 
NCT03326674
ODO-TE-B301
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Undecided
Plan Description: Currently under evaluation by the organization
Odonate Therapeutics, LLC
Odonate Therapeutics, LLC
Not Provided
Study Director: Joseph O'Connell, MD Odonate Therapeutics, LLC
Odonate Therapeutics, LLC
December 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP